Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Khim ; 70(2): 99-108, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38711409

ABSTRACT

Platelet functional activity was assessed in healthy volunteers (HV, n=92), patients with stable angina pectoris (SA, n=42) and acute coronary syndrome (ACS, n=73), treated with acetylsalicylic acid (ASA) + clopidogrel and ASA + ticagrelor, respectively. In all HV and patients we have compared parameters of platelet aggregation (maximum light transmission and velocity, Tmax and Vmax) and parameters, characterizing exposure of platelet activation markers, evaluated by flow cytometry. HV platelets were activated by 10 µM, 1 µM TRAP, and 20 µM, 5 µM, 2.5 µM ADP; patient platelets were activated by 10 µM TRAP and by 20 µM and 5 µM ADP. Strong and significant correlations between the aggregation and flow cytometry parameters (the r correlation coefficient from 0.4 up to >0.6) most frequently were registered in HV platelet during activation by 1 µM TRAP and in SA patients during platelet activation by 20 µM and 5 µM ADP. However, in many other cases these correlations were rather weak (r < 0.3) and sometimes statistically insignificant. In HV the differences in PAC-1 binding parameters between platelets activated by 10 µM TRAP (the strongest agonist) and all ADP concentrations were negligible (≤ 10%), while CD62P binding (at all ADP concentrations) and LTA parameters for (5 µM and 2.5 µM ADP) were significantly lower (by 40-60%). Antiplatelet therapy in patients decreased all parameters as compared to HV, but to varying extents. For 10 µM TRAP the MFI index for PAC-1 binding (40-50% decrease) and for both ADP concentrations the Tmax values (60-85% decrease) appeared to be the most sensitive in comparison with the other parameters that decreased to a lesser extent. The data obtained indicate a possibility of inconsistency between different LTA and flow cytometry parameters in assessing platelet activity and efficacy of antiplatelet drugs.


Subject(s)
Acute Coronary Syndrome , Aspirin , Blood Platelets , Clopidogrel , Flow Cytometry , Platelet Aggregation Inhibitors , Platelet Aggregation , Humans , Platelet Aggregation Inhibitors/pharmacology , Platelet Aggregation/drug effects , Male , Aspirin/pharmacology , Aspirin/therapeutic use , Female , Blood Platelets/drug effects , Blood Platelets/metabolism , Middle Aged , Clopidogrel/pharmacology , Aged , Acute Coronary Syndrome/drug therapy , Acute Coronary Syndrome/blood , Adult , Ticagrelor/pharmacology , Ticagrelor/therapeutic use , Platelet Function Tests/methods , Platelet Activation/drug effects , Angina, Stable/drug therapy , Angina, Stable/blood , Adenosine Diphosphate/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...